Treatment of fungal infections: an update

IF 0.3 Q4 PEDIATRICS
A. Giannattasio, C. Veropalumbo, L. Mari, Valentina Marra, Maria Vittoria Andreucci, L. Capasso, F. Raimondi
{"title":"Treatment of fungal infections: an update","authors":"A. Giannattasio, C. Veropalumbo, L. Mari, Valentina Marra, Maria Vittoria Andreucci, L. Capasso, F. Raimondi","doi":"10.7363/030242","DOIUrl":null,"url":null,"abstract":"Fungal infections represent a serious problem in neonatal intensive care units (NICUs) worldwide. Preterm infants are a vulnerable population for major events and adverse sequelae from fungal sepsis. The primary fungus of concern in neonates is C. albicans , whose colonization is associated with devastating complication and high rate of mortality. Among the risk factors responsible for development of invasive fungal infections, previous mucosal and skin colonization are of primary importance. Fungal colonization in neonates may be secondary to either maternal transmission or nosocomial acquisition in the nursery. Antifungal prophylaxis is currently applied in different NICUs and in various patients groups with successful results. Prophylactic drugs can include oral nystatin and oral or intravenous fluconazole. To date, antifungal prophylaxis with fluconazole is the recommended approach for neonates lower than 1,000 g and/or 27 weeks’ gestation or less, manly in NICUs with relatively high frequency of invasive candidiasis. First-line treatment of invasive fungal infections includes amphotericin B deoxycholate, lipid preparations of amphotericin B, fluconazole, or micafungin. However, data on pharmacokinetic, schedule treatment and appropriate dosage of antifungal agents in neonates, mainly in premature, are still limited. Future strategies to reduce neonatal morbidity and mortality derived from invasive fungal infections include new echinocandins not yet approved for neonatal use (caspofungin or anidulafungin) and other adjuvant treatments as intravenous immunoglobulin, lactoferrin or probiotics. Since current therapies for systemic fungal diseases are not universally successful and morbidity remains high, future efforts will be also focused on better prevention of fungal diseases and understanding of appropriate dosing schedule of the available antifungal agents. Proceedings of the 10 th International Workshop on Neonatology · Cagliari (Italy) · October 22 nd -25 th , 2014 ·  The last ten years, the next ten years in Neonatology Guest Editors: Vassilios Fanos, Michele Mussap, Gavino Faa, Apostolos Papageorgiou","PeriodicalId":51914,"journal":{"name":"Journal of Pediatric and Neonatal Individualized Medicine","volume":"3 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2014-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric and Neonatal Individualized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7363/030242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 1

Abstract

Fungal infections represent a serious problem in neonatal intensive care units (NICUs) worldwide. Preterm infants are a vulnerable population for major events and adverse sequelae from fungal sepsis. The primary fungus of concern in neonates is C. albicans , whose colonization is associated with devastating complication and high rate of mortality. Among the risk factors responsible for development of invasive fungal infections, previous mucosal and skin colonization are of primary importance. Fungal colonization in neonates may be secondary to either maternal transmission or nosocomial acquisition in the nursery. Antifungal prophylaxis is currently applied in different NICUs and in various patients groups with successful results. Prophylactic drugs can include oral nystatin and oral or intravenous fluconazole. To date, antifungal prophylaxis with fluconazole is the recommended approach for neonates lower than 1,000 g and/or 27 weeks’ gestation or less, manly in NICUs with relatively high frequency of invasive candidiasis. First-line treatment of invasive fungal infections includes amphotericin B deoxycholate, lipid preparations of amphotericin B, fluconazole, or micafungin. However, data on pharmacokinetic, schedule treatment and appropriate dosage of antifungal agents in neonates, mainly in premature, are still limited. Future strategies to reduce neonatal morbidity and mortality derived from invasive fungal infections include new echinocandins not yet approved for neonatal use (caspofungin or anidulafungin) and other adjuvant treatments as intravenous immunoglobulin, lactoferrin or probiotics. Since current therapies for systemic fungal diseases are not universally successful and morbidity remains high, future efforts will be also focused on better prevention of fungal diseases and understanding of appropriate dosing schedule of the available antifungal agents. Proceedings of the 10 th International Workshop on Neonatology · Cagliari (Italy) · October 22 nd -25 th , 2014 ·  The last ten years, the next ten years in Neonatology Guest Editors: Vassilios Fanos, Michele Mussap, Gavino Faa, Apostolos Papageorgiou
真菌感染的治疗:最新进展
真菌感染是全世界新生儿重症监护病房(NICUs)的一个严重问题。早产儿是真菌败血症重大事件和不良后遗症的易感人群。新生儿关注的主要真菌是白色念珠菌,其定植与破坏性并发症和高死亡率有关。在造成侵袭性真菌感染的危险因素中,先前的粘膜和皮肤定植是最重要的。新生儿的真菌定植可能继发于母体传播或托儿所的医院获得。抗真菌预防目前应用于不同的新生儿重症监护病房和不同的患者群体,并取得了成功的结果。预防性药物包括口服制霉菌素和口服或静脉注射氟康唑。迄今为止,氟康唑抗真菌预防是小于1000g和/或妊娠27周或更短的新生儿的推荐方法,尤其是在侵袭性念珠菌病发病率相对较高的新生儿重症监护病房。侵袭性真菌感染的一线治疗包括两性霉素B脱氧胆酸酯、两性霉素B脂质制剂、氟康唑或米卡芬宁。然而,关于新生儿(主要是早产儿)抗真菌药物的药代动力学、治疗方案和适当剂量的数据仍然有限。未来降低侵袭性真菌感染引起的新生儿发病率和死亡率的策略包括尚未批准用于新生儿的新刺白菌素(caspofungin或anidulafungin)和其他辅助治疗,如静脉注射免疫球蛋白、乳铁蛋白或益生菌。由于目前对全身性真菌疾病的治疗并不普遍成功,发病率仍然很高,未来的努力还将集中在更好地预防真菌疾病和了解现有抗真菌药物的适当剂量计划上。第十届国际新生儿科研讨会论文集·卡利亚里(意大利)·2014年10月22日至25日·过去的十年,未来的十年在新生儿科客座编辑:Vassilios Fanos, Michele Mussap, Gavino Faa, Apostolos Papageorgiou
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
25.00%
发文量
0
审稿时长
12 weeks
期刊介绍: The Journal of Pediatric and Neonatal Individualized Medicine (JPNIM) is a peer-reviewed interdisciplinary journal which provides a forum on new perspectives in pediatric and neonatal medicine. The aim is to discuss and to bring readers up to date on the latest in research and clinical pediatrics and neonatology. Special emphasis is on developmental origin of health and disease or perinatal programming and on the so-called ‘-omic’ sciences. Systems medicine blazes a revolutionary trail from reductionist to holistic medicine, from descriptive medicine to predictive medicine, from an epidemiological perspective to a personalized approach. The journal will be relevance to clinicians and researchers concerned with personalized care for the newborn and child. Also medical humanities will be considered in a tailored way. Article submission (original research, review papers, invited editorials and clinical cases) will be considered in the following fields: fetal medicine, perinatology, neonatology, pediatrics, developmental programming, psychology and medical humanities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信